HomeCompareSPHRY vs MO

SPHRY vs MO: Dividend Comparison 2026

SPHRY yields 66.67% · MO yields 6.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SPHRY wins by $818.5K in total portfolio value
10 years
SPHRY
SPHRY
● Live price
66.67%
Share price
$3.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$898.6K
Annual income
$227,458.53
Full SPHRY calculator →
MO
Altria Group Inc.
● Live price
6.36%
Share price
$65.99
Annual div
$4.20
5Y div CAGR
22.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80.1K
Annual income
$30,159.17
Full MO calculator →

Portfolio growth — SPHRY vs MO

📍 SPHRY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSPHRYMO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SPHRY + MO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SPHRY pays
MO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRY
Annual income on $10K today (after 15% tax)
$5,666.67/yr
After 10yr DRIP, annual income (after tax)
$193,339.75/yr
MO
Annual income on $10K today (after 15% tax)
$540.99/yr
After 10yr DRIP, annual income (after tax)
$25,635.29/yr
At 15% tax rate, SPHRY beats the other by $167,704.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRY + MO for your $10,000?

SPHRY: 50%MO: 50%
100% MO50/50100% SPHRY
Portfolio after 10yr
$489.4K
Annual income
$128,808.85/yr
Blended yield
26.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MO right now

SPHRY
No analyst data
Altman Z
9.3
Piotroski
3/9
MO
Analyst Ratings
16
Buy
9
Hold
1
Sell
Consensus: Buy
Price Target
$61.25
-7.2% upside vs current
Range: $47.00 — $68.00
Altman Z
3.2
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRY buys
0
MO buys
0
No recent congressional trades found for SPHRY or MO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSPHRYMO
Forward yield66.67%6.36%
Annual dividend / share$2.00$4.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.6%
Portfolio after 10y$898.6K$80.1K
Annual income after 10y$227,458.53$30,159.17
Total dividends collected$759.4K$74.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: SPHRY vs MO ($10,000, DRIP)

YearSPHRY PortfolioSPHRY Income/yrMO PortfolioMO Income/yrGap
1← crossover$17,367$6,666.67$10,570$780.30+$6.8KSPHRY
2$29,403$10,820.35$11,381$1,032.90+$18.0KSPHRY
3$48,582$17,120.96$12,535$1,392.73+$36.0KSPHRY
4$78,421$26,438.17$14,193$1,920.91+$64.2KSPHRY
5$123,795$39,884.53$16,618$2,723.68+$107.2KSPHRY
6$191,303$58,842.62$20,263$3,993.80+$171.0KSPHRY
7$289,676$84,982.16$25,936$6,098.36+$263.7KSPHRY
8$430,218$120,263.91$35,166$9,775.01+$395.1KSPHRY
9$627,260$166,927.04$51,026$16,597.78+$576.2KSPHRY
10$898,627$227,458.53$80,113$30,159.17+$818.5KSPHRY

SPHRY vs MO: Complete Analysis 2026

SPHRYStock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRY Calculator →

MOConsumer Staples

Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company provides cigarettes primarily under the Marlboro brand; cigars and pipe tobacco principally under the Black & Mild brand; and moist smokeless tobacco products under the Copenhagen, Skoal, Red Seal, and Husky brands, as well as provides on! oral nicotine pouches. It sells its tobacco products primarily to wholesalers, including distributors; and large retail organizations, such as chain stores. Altria Group, Inc. was founded in 1822 and is headquartered in Richmond, Virginia.

Full MO Calculator →
📬

Get this SPHRY vs MO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRY vs SCHDSPHRY vs JEPISPHRY vs OSPHRY vs KOSPHRY vs MAINSPHRY vs PMSPHRY vs BTISPHRY vs PG

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.